Kenvue Inc (KVUE)
21.85
+0.33
(+1.53%)
USD |
NYSE |
Jun 11, 16:00
21.84
-0.01
(-0.05%)
Pre-Market: 06:50
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 41.95B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 22.76% |
| Valuation | |
| PE Ratio | 39.73 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.748 |
| Price to Book Value | 4.173 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.205 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.8582 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
Edit
| Kenvue is the world’s largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power. |
| URL | https://www.kenvue.com |
| Investor Relations URL | https://investors.kenvue.com/overview/default.aspx |
| HQ State/Province | New Jersey |
| Sector | Consumer Staples |
| Industry | Personal Care Products |
| Next Earnings Release | Aug. 06, 2025 (est.) |
| Last Earnings Release | May. 08, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 14, 2025 |
Ratings
Profile
Edit
| Kenvue is the world’s largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson’s consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of silos within consumer health, such as cough, cold and allergy care, pain management, face and body care, and oral care, as well as women’s health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson’s, Aveeno, and Neutrogena. Despite playing in a fragmented industry with intense competition and changing consumer preferences, many of Kenvue’s brands are the global leader in their respective segment thanks to their strong brand power. |
| URL | https://www.kenvue.com |
| Investor Relations URL | https://investors.kenvue.com/overview/default.aspx |
| HQ State/Province | New Jersey |
| Sector | Consumer Staples |
| Industry | Personal Care Products |
| Next Earnings Release | Aug. 06, 2025 (est.) |
| Last Earnings Release | May. 08, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 14, 2025 |